Symbiotec Pharmalab Limited

Total Issue Size

₹1,757 Cr

1,77,86,442 shares

Fresh Issue

₹150.27 Cr

15,21,261 shares

Offer for Sale

₹1,606.72 Cr

1,62,65,181 shares

Face Value

₹2 per share

Issue Type

Book-built IPO

Listing At

BSE, NSE

Shares Pre-Issue

6,27,34,851

Shares Post-Issue

6,42,56,112

1. Offer opens

   24 Aug 2026

2. Offer closes

   27 Aug 2026

3. Allotment

   28 Aug 2026

4. Listing

   1 Sept 2026

• Anchor29.9%53,25,909 shares
• QIB20.0%35,50,607 shares
• HNI15.0%26,62,956 shares
• Retail34.9%62,13,563 shares
• Employee0.2%33,407 shares

Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions. With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations. As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres. Symbiotec Pharmalab focuses on research-driven manufacturing, quality compliance, and sustainable production processes. It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards. Competitive Strengths: Global leadership in corticosteroid and steroidal hormone APIs. Long-standing relationships with domestic and international customers. Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record. Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers. Ability to leverage its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings.

• Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company (₹112.50 Cr)
• General Corporate Purposes (₹29.53 Cr)
• Issue Expenses (₹105.02 Cr)

• <p>Anil Satwani
• Kashish Satwani
• Sushil Satwani
• Satwani Holdings LLP</p>

Book running lead managers

• JM Financial Ltd.
• Avendus Capital Pvt.Ltd.
• Motilal Oswal Investment Advisors Ltd.
• Nomura Financial Advisory & Securities (India) Pvt.Ltd.

Registered office

385/2,, Pigdamber, Rau,, Mhow,, Indore, Madhya Pradesh, 453331

• DRHPDraft Red Herring Prospectus
• RHPRed Herring Prospectus
• AnchorAnchor Investor List